

GI Histology Report



Patient Name Johnson, Thomas F.	Accession Number QS17-00001	Procedure Date 01/01/2017
Date of Birth (Age) 01/01/1960 (57)	Requesting Facility ABC GI Specialists	Received Date 01/01/2017
EMR # 12345	Requesting Physician Joseph Smith, M.D.	Report Date 01/02/2017
Patient Phone 888.555.1212	Referring Physician Fax #	Lab Case # SP17-00001
Referring Physician	Clinical Information	
ICD Code(s) K21.9, R13.10, K31.7, C15.9	Patient History Of : Dysphagia. Symptoms : GERD	




Quantum Pathology, LLC
318 Bear Hill Road
Watham, MA 02451
Phone: 781.373.1689 Fax: 781.373.2078

CLIA#: 22D2081781
Medical Director: Lindsay B. Hardy, M.D.

Diagnostic Anatomic Map



B. Invasive adenocarcinoma.



B. Invasive adenocarcinoma.

A. Stomach, Body, Corpus

B. Esophagus, Stricture

Diagnosis & Interpretation

A. Stomach, Body, Corpus, Polyp, Snare Biopsy Fundic gland polyp.

The biopsy shows oxyntic (fundic) type mucosa with cyst formation. Fundic gland polyps causes include proton pump inhibitor therapy atrophic gastritis and rare conditions such as ZE syndrome.

B. Esophagus, Stricture, Biopsies Adenocarcinoma

- Moderately differentiated.
- Her2-neu Immunoperoxidase stains are positive.

Gross Description

A. Stomach, Body, Corpus, Polyp, Snare Biopsy - Received in formalin with the patient's name labeled "Corpus Polyp" consists of multiple fragments of tan-pink soft tissue measuring 0.8 x 0.4cm in aggregate. Totally submitted in 1 cassette.

B. Esophagus, Stricture, Biopsies - Received in formalin with the patient's name labeled "Esophagus, Stricture" consists of multiple fragments of tan-pink soft tissue measuring 1.0 x 0.7cm in aggregate. Totally submitted in 1 cassette.

Dr. May Azar
Final Report Electronically signed on 01/02/2017 at 12:00 PM

Technical Component performed at
Quantum Pathology LLC

129 Morgan Dr
Norwood, MA 02062
CLIA# 22D2081785

The accuracy and adequacy of immunohistochemistry controls have been confirmed upon review.

These Immunohistochemical tests and their performance characteristics are determined by Quantum Pathology LLC, 129 Morgan Dr Norwood, MA 02062. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA) as such approval is not required. These tests are permitted for clinical purposes and should not be regarded as purely investigational or for research. Quantum Pathology LLC is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.